Prosecution Insights
Last updated: July 17, 2026
Application No. 17/630,106

COMPOSITIONS AND METHODS FOR INHIBITING NEOINTIMAL FORMATION

Non-Final OA §103§112
Filed
Jan 25, 2022
Priority
Jul 26, 2019 — provisional 62/878,980 +1 more
Examiner
COFFA, SERGIO
Art Unit
1658
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
University of Virginia Patent Foundation
OA Round
3 (Non-Final)
61%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
94%
With Interview

Examiner Intelligence

Grants 61% of resolved cases
61%
Career Allowance Rate
449 granted / 734 resolved
+1.2% vs TC avg
Strong +33% interview lift
Without
With
+33.1%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
69 currently pending
Career history
789
Total Applications
across all art units

Statute-Specific Performance

§101
0.9%
-39.1% vs TC avg
§103
47.4%
+7.4% vs TC avg
§102
12.3%
-27.7% vs TC avg
§112
9.5%
-30.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 734 resolved cases

Office Action

§103 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 5/26/2026 has been entered. Claim Status Claims 1-12 and 17-19 are pending. Claims 13-16 and 20-22 have been canceled. Claims 1-3, 12 and 18 have been amended. Claims 1-2 are allowable. Claims 8-12 and 17-19, previously withdrawn from consideration as a result of a restriction requirement, require all the limitations of an allowable claim. Pursuant to the procedures set forth in MPEP § 821.04(a), the restriction requirement between inventions I, III and V, as set forth in the Office action mailed on 11/7/2024, is hereby withdrawn and claims 8-12 and 17-19 are hereby rejoined and fully examined for patentability under 37 CFR 1.104. In view of the withdrawal of the restriction requirement, applicant(s) are advised that if any claim presented in a divisional application is anticipated by, or includes all the limitations of, a claim that is allowable in the present application, such claim may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Once the restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. See In re Ziegler, 443 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01. Claim Objections Claims 8-10 are objected to because of the following informalities: The acronym “SMC” should be spelled out the first time it is mentioned in the claims. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 11-12 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 11 recites the limitation "the peptide of….claim 2" in lines 1-2. There is insufficient antecedent basis for this limitation in the claim. Claim 12, which depends from claim 11, is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as this claim incorporates by dependency the indefiniteness of claim 11. Claim Rejections - 35 USC § 103 The rejection of claim 1 under 35 U.S.C. 103 as being unpatentable over Dyce et al. is withdrawn in view of the amendments to the claims. The rejection of claims 1-2 under 35 U.S.C. 103 as being unpatentable over Dyce et al. in view of Pepscan is withdrawn in view of the amendments to the claims. Allowable Subject Matter Claims 1-2 and 17-19 are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SERGIO COFFA whose telephone number is (571)270-3022. The examiner can normally be reached M-F: 6AM-4PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, MELISSA FISHER can be reached at 571-270-7430. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SERGIO COFFA Ph.D./ Primary Examiner Art Unit 1658 /SERGIO COFFA/Primary Examiner, Art Unit 1658
Read full office action

Prosecution Timeline

Jan 25, 2022
Application Filed
Feb 13, 2025
Non-Final Rejection mailed — §103, §112
Aug 13, 2025
Response Filed
Aug 21, 2025
Final Rejection mailed — §103, §112
Feb 23, 2026
Notice of Allowance
May 26, 2026
Request for Continued Examination
May 27, 2026
Response after Non-Final Action
Jun 18, 2026
Non-Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12678541
CURABLE FIBRINOGEN AND USES THEREOF
3y 9m to grant Granted Jul 14, 2026
Patent 12653866
URI Agonist/Vasodilator
2y 6m to grant Granted Jun 16, 2026
Patent 12648571
COMPOSITIONS INCLUDING ANTIMICROBIAL POLYMER- PEPTIDE CONJUGATES AND USES THEREOF
3y 10m to grant Granted Jun 09, 2026
Patent 12643935
PD-L1 BINDING PEPTIDES
3y 7m to grant Granted Jun 02, 2026
Patent 12630587
A NEW ANTIBIOTIC SELECTIVELY KILLS GRAM-NEGATIVE PATHOGENS
4y 0m to grant Granted May 19, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
61%
Grant Probability
94%
With Interview (+33.1%)
2y 11m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 734 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month